| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13D |
| 12 Nov 2026 | 8-K: Results of Operations and Financial Condition |
| 12 Nov 2026 | 10-Q |
| 12 Nov 2026 | SCHEDULE 13G/A |
| 10 Nov 2026 |
8-K: Other Events
Azitra, Inc. to Present Research at BIO-Europe® Showing ATR-COSF Reduced Fine Lines and Improved Elasticity in Ex Vivo Human Skin Models |
| 29 Oct 2026 |
8-K: Other Events
Azitra, Inc. Expands Eligibility for ATR-04 Phase 1/2 Clinical Trial to Include Patients with Rashes due to KRAS and MEK Inhibitors |
| 26 Oct 2026 |
8-K: Other Events
ATR-COSF uses a supernatant based formulation containing an active recombinant human domain of the protein, filaggrin. |
| 22 Oct 2026 |
8-K: Material Modification to Rights of Security Holders; Amendments to Articles/Bylaws; Change in Fiscal Year
Azitra, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify: |
| 01 Oct 2026 |
8-K: Other Events
BRANFORD, Conn. – October 1, 2026 — Azitra, Inc. (“Azitra” or the “Company”) (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the comp... |
| 28 Sep 2026 |
8-K: Entry into a Material Definitive Agreement
Azitra, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with A.G.P./Alliance Global Partners (the “Sales Agent”), as follows: |
| 28 Sep 2026 | 424B5 |
| 08 Sep 2026 |
8-K: Regulation FD Disclosure
BRANFORD, Conn. – September 8, 2026 — Azitra, Inc. (“Azitra” or the “Company”) (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology and high value cosmetic... |
| 21 Aug 2026 |
8-K: Other Events
BRANFORD, Conn. – August 21, 2026 — Azitra, Inc. (“Azitra” or the “Company”) (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology and high value cosmetic p... |
| 14 Aug 2026 | SCHEDULE 13G |
| 14 Aug 2026 | SCHEDULE 13G |
| 12 Aug 2026 |
8-K: Results of Operations and Financial Condition
BRANFORD, Conn. – August 12, 2026 — Azitra, Inc. (“Azitra” or the “Company”) (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology and high value cosmetic p... |
| 12 Aug 2026 | 10-Q |
| 15 Jul 2026 |
8-K: Other Events
Azitra, Inc. Announces Breakthrough Repeat Dose and Anti-Wrinkle Ex Vivo Results for ATR-COSF Program, Demonstrating Increased Distribution and Elasticity |
| 25 Jun 2026 | SCHEDULE 13G |
| 24 Jun 2026 | SCHEDULE 13D |
Loading...